300 reports of this reaction
2.0% of all PEGVALIASE PQPZ reports
#15 most reported adverse reaction
ANAPHYLACTIC REACTION is the #15 most commonly reported adverse reaction for PEGVALIASE PQPZ, manufactured by BioMarin Pharmaceutical Inc.. There are 300 FDA adverse event reports linking PEGVALIASE PQPZ to ANAPHYLACTIC REACTION. This represents approximately 2.0% of all 14,737 adverse event reports for this drug.
Patients taking PEGVALIASE PQPZ who experience anaphylactic reaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAPHYLACTIC REACTION is a less commonly reported adverse event for PEGVALIASE PQPZ, but still significant enough to appear in the safety profile.
In addition to anaphylactic reaction, the following adverse reactions have been reported for PEGVALIASE PQPZ:
The following drugs have also been linked to anaphylactic reaction in FDA adverse event reports:
ANAPHYLACTIC REACTION has been reported as an adverse event in 300 FDA reports for PEGVALIASE PQPZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAPHYLACTIC REACTION accounts for approximately 2.0% of all adverse event reports for PEGVALIASE PQPZ, making it a notable side effect.
If you experience anaphylactic reaction while taking PEGVALIASE PQPZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.